From: Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma
Expected overall adverse event (Proportion)
Adverse event rate (Null proportion)
Lower critical value
Power
5%
34%
1
88.2%
10%
65.9%
15%
44.3%
20%
27.5%